Freenome (NASDAQ:FRNM) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Freenome (NASDAQ:FRNM) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $18.00.

Several analysts have weighed in on FRNM shares. Leerink Partners started coverage on shares of Freenome in a research note on Friday, August 14th. They issued an “outperform” rating and a $18.00 price target for the company. BTIG Research initiated coverage on Freenome in a research note on Monday, August 17th. They set a “buy” rating and a $17.00 price objective on the stock. Jefferies Financial Group began coverage on Freenome in a report on Monday, August 17th. They issued a “buy” rating and a $17.00 price objective on the stock. Guggenheim began coverage on Freenome in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Weiss Ratings initiated coverage on Freenome in a report on Monday. They set a “sell (d+)” rating for the company.

Freenome Stock Performance

Shares of FRNM traded up $0.21 during mid-day trading on Tuesday, reaching $13.99. The company’s stock had a trading volume of 475,972 shares, compared to its average volume of 870,695. The firm has a market cap of $114.16 million, a price-to-earnings ratio of -233.13 and a beta of 0.35. Freenome has a 52 week low of $9.97 and a 52 week high of $14.26.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.